 Home > Medical News > Latest Medical News > Supporting the submission of new drug applications this year, the key clinical trial results of innovative RNAi therapy are positive

Supporting the submission of new drug applications this year, the key clinical trial results of innovative RNAi therapy are positive

 Last Update: 2021-11-13
 Source: Internet
 Author: User

Tags

2 3 dibromobutane

eca medical instruments

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 5, Dicerna Pharmaceuticals announced that a pivotal clinical trial of the RNAi drug candidate nedosiran has achieved positive results

Primary hyperoxaluria (PH) is an ultra-rare and life-threatening genetic disease.

Nedosiran binds to mRNA to inhibit the expression of liver lactate dehydrogenase (LDH), which is a key metabolic enzyme that leads to the overproduction of oxalate

▲In patients with PH1 subtypes, nedosiran significantly reduced oxalate excretion in the urine of patients (picture source: Dicerna's official website)

This phase 2 clinical trial reached the primary endpoint.

In the trial, nedosiran was generally well tolerated, and the overall adverse event (AE) characteristics were consistent with previous trial data

Dr.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.